PARIS (dpa-AFX) - Sanofi (SNY) announced data from a 60-week, open-label study that compared three intensified insulin regimens added to oral therapy for uncontrolled type 2 diabetes and found that using two regimens including Lantus (insulin glargine [rDNA origin] injection) and Apidra (insulin glulisine [rDNA origin] injection) lowered blood glucose levels compared to premixed insulin with less hypoglycemia and improvement in diabetes-specific quality of life.
The company said that the study results supported the non-inferiority of Lantus plus up to 1 injection of Apidra versus two-injections of premixed insulin, while in the Lantus plus up to 3 injections of Apidra® arm, superiority versus premixed insulin was not shown.
Copyright RTT News/dpa-AFX